Navigation Links
Einstein scientists find crucial molecule involved in spread of breast cancer
Date:6/8/2011

June 8, 2011 (Bronx, NY) Researchers at Albert Einstein College of Medicine of Yeshiva University have identified a key player in the spread of breast cancer. The findings, published today in the online edition of Nature, identify a critical molecule that helps cancer spread beyond the primary tumor. The research highlights a potential new strategy against metastatic disease. The study's senior author is Jeffrey Pollard, Ph.D., professor of developmental and molecular biology and of obstetrics & gynecology and women's health at Einstein. He also holds the Louis Goldstein Swan Chair in Women's Cancer Research and is the deputy director of the Albert Einstein Cancer Center.

People rarely die from their primary (original) tumor. Instead, most cancer deaths occur because the cancer has spread, or metastasized, to other parts of the body. "By focusing on sites where cancer had spread, we were able to detect a molecule that stimulates metastasis," said Dr. Pollard. "This raises the possibility that metastasis could be kept from progressing or even prevented if the stimulating molecule could be blocked. This we achieved in mouse models of breast cancer."

Metastasis begins when cells break away from the primary tumor and gain the ability to move on their own. These cells invade nearby blood vessels (a process known as intravasation) and are carried by the bloodstream to other parts of the body. The bloodborne tumor cells then escape from vessels in a process known as extravasation. Once these tumor cells escape from the vessels, they seed new and deadly tumors that grow in these distant locations.

In previous studies, Dr. Pollard and his research team have shown that macrophages immune system cells whose functions include fighting infections actually promote the spread of cancer. His research has shown that macrophages not only assist tumor cells during both intravasation and extravasation but also help those wayward cells take root in their new locations and grow into metastatic tumors. In the current study, Dr. Pollard and colleagues investigated the process by which these macrophages are recruited to metastatic sites and subsequently promote tumor-cell extravasation, seeding and tumor growth.

Using models of human and mouse breast cancer, the researchers demonstrated that when breast tumor cells travel to the lung, these cells secrete CCL2, a chemokine molecule (i.e., one that attracts cells). CCL2 attracts immune cells called inflammatory monocytes -- in particular, those bearing receptors for CCL2, which then develop into macrophages. The monocytes and macrophages "invited" by CCL2 signaling then facilitate extravasation the critical step in metastasis in which bloodborne tumor cells cross the vessel wall and implant in nearby tissue. One way monocytes help tumor cells escape from blood vessels and cause metastasis, the Einstein researchers found, is by secreting vascular endothelial growth factor, or VEGF, a substance that makes blood vessels leaky at the site where tumor cells exit from them.

Once the tumor cells are seeded, inflammatory monocytes continue to flock to the metastatic site now attracted by CCL2 secreted not only by the tumor cells but also by nearby lung tissue that the tumor cells have targeted. In turn, these continuously recruited monocytes and the resultant macrophages promote the growth of the emerging metastatic tumor.

To confirm their findings, the researchers used anti-CCL2 antibodies to suppress CCL2 signaling in a mouse model of human metastasis with striking results. In lungs challenged with metastatic tumor cells, the anti-CCL2 antibodies inhibited the influx of inflammatory monocotyes and macrophages to the metastatic sites, and the number of metastatic sites that developed in the lungs was markedly reduced. In addition, the mice lived much longer when CCL2 signaling was blocked.

"These findings have potential implications for therapy, since in human breast cancer we know that CCL2 expression and macrophage infiltration are associated with poor prognosis and metastatic disease," said Dr. Pollard. "If we can develop ways to inhibit these processes, we might be able to slow or stop breast cancer from spreading."


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Einstein secures $11 million to continue research on brain aging and Alzheimers disease
2. Einstein Montefiore lung specialist to receive award for work with 9/11 rescue workers
3. Feinstein scientists identify abnormal disease pathway in dystonia
4. Susan Band Horwitz, Ph.D., of Einstein, receives lifetime achievement award in cancer research
5. Einstein-Montefiore researcher will test nanoparticles against pancreatic cancer
6. ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA
7. Feinstein Institute to share $5M US Department of Defense grant
8. Einstein scientist awarded $4 million to develop genetic strategy to combat tuberculosis
9. Einstein awarded NIH grant to study drug-resistant TB
10. NIH awards $10M to Einstein for diabetes research
11. Scientists create humanized mouse model for hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways ... and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. ... say grilling is their favorite way to cook a hot dog, far outpacing other ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... hosted members and suppliers for its inaugural Member Conference at the Paris Hotel ... of elevating the operational health of America’s healthcare providers. , The conference was ...
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, ... who lost their lives in military battle for the country. The nonprofit Hope ... to provide more programs that empower independence for disabled military veterans, as well as ...
(Date:5/26/2016)... ... ... There are nearly 14.5 million people living with and beyond cancer in the ... 2016, communities around the world will gather to recognize these cancer survivors as part ... is an annual worldwide Celebration of Life that is held on the first Sunday ...
(Date:5/26/2016)... ... 2016 , ... Dr. James Maisel will present on “Macular ... on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. The presentation ... of New York , is a Board Certified ophthalmologist who completed his fellowship ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... -- According to market research "Global Insulin ... Forecast to 2022 - Industry Insights by Type (Insulin ... P&S Market Research, the global insulin delivery device market ... is expected to grow at a CAGR of 6.6% ... is expected to witness the fastest growth at a ...
(Date:5/25/2016)... England , May 25, 2016 ... company employing the precision of circulating tumour DNA ... today announces the appointment of Professor Clive ... provide medical leadership across the clinical development programme, ... Inivata,s products help deliver significant improvements in clinical ...
Breaking Medicine Technology: